Shuttle Pharmaceuticals Holdings, Inc.
SHPHNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | −$11.9M | −$7.7M | −$5.9M | −$2.6M | −$1.7M |
| Net income | −$11.7M | −$9.1M | −$6.6M | −$3.0M | −$1.2M |
| Total assets | $10.5M | $2.5M | $6.0M | $8.7M | $651,641 |
| Total liabilities | $8.2M | $1.8M | $1.9M | $975,676 | $2.3M |
| Equity | $2.3M | $709,152 | $4.1M | $7.7M | −$1.6M |
| EPS (diluted) | $-7.16 | $-82.60 | $-3.53 | $-0.29 | $-0.12 |
| Shares out. | 4.1M | 16.8M | 13.7M | 13.6M | 9.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −519.9%
- Return on assets
- −111.9%
- Return on capital (ROCE)
- −474.9%
- Liabilities / assets
- 78.5%
- Debt / equity
- 3.65×
- Book value / share
- $0.55
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -26.44distress
- Accruals / assets
- −21.4%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 13, 2024
- NT 10-Qmissed a reporting deadline ↗May 15, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Armistice Capital, LlcPassive (13G)Aug 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Jung MiraOfficer — Chief Scientific Officer | May 1, 2024 | Grant | 598 | $11.28 |
| Senanayake ChrisDirector | Dec 29, 2022 | Sell | 1,626 | $1.60 |
| Vander Hoek MichaelOfficer — Chief Financial Officer | Mar 8, 2024 | Grant | 100,000 | $0.00 |
| Brown MiltonDirector | Dec 13, 2023 | Sell | 2,921 | $0.46 |
| Jacobs BetteDirector | Dec 13, 2023 | Sell | 4,157 | $0.46 |
| Dritschilo AnatolyOfficer — CEO and Chairman | Aug 14, 2023 | Gift | 2.1M | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 441,245 | 1.0 | +279.6% |
| Apr 30, 2026 | 116,241 | 1.0 | +63.3% |
| Apr 15, 2026 | 71,193 | 1.0 | -38.6% |
| Mar 31, 2026 | 115,865 | 1.0 | +196.0% |
| Mar 13, 2026 | 39,143 | 1.0 | -13.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 27, 2026
- Entered a material agreement · Completed an acquisition or disposition · Unregistered equity sale · Modified shareholder rights · Director / officer change · Amended charter or bylawsMay 7, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureMay 1, 2026
- Entered a material agreement · Regulation FD disclosureMar 10, 2026
- Results of operationsFeb 17, 2026
- Director / officer changeFeb 2, 2026
- Director / officer changeJan 12, 2026
- Entered a material agreement · Unregistered equity saleDec 29, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.